Business
Adagio Medical Ultralow Temperature Ablation U.S. Pivotal Study Results to be Presented in Late-Breaking Session at Heart Rhythm Society 2026
LAGUNA HILLS, Calif., April 01, 2026--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that the pivotal results from the FULCRUM-VT study have been accepted for presentation in a late-breaking clinical science session at Heart Rhythm 2026 (HRS), the annual meeting of the Heart Rhythm Society. This is the first Investigational Device Exemption (IDE) study powere
About this update from Adagio Medical Holdings, Inc
[{"type":"text","content":"LAGUNA HILLS, Calif., April 01, 2026--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that the pivotal results from the FULCRUM-VT study have been accepted for presentation in a late-breaking clinical science session at Heart Rhythm 2026 (HRS), the annual meeting of the Heart Rhythm Society. This is the first Investigational Device Exemption (IDE) study powered to evaluate the safety and effectiveness of Ultra-Low Temperature Ablation ("ULTA", formerly "ULTC") for the treatment of scar-related ventricular tachycardia (VT) in both ischemic and non-ischemic population.","length":768,"tagName":"p"},{"type":"text","content":""Having FULCRUM-VT data selected for a late-breaking session at HRS is a testament to the significance of this work," said Matthew Hakimi, M.D., Cardiac Electrophysiologist, Cedars Sinai Medical Center and Medical Director at Adagio Medical. "On behalf of the entire Adagio team, I want to recognize the investigators, research coordinators, and patients whose dedication and perseverance made this study possible. Completing FULCRUM-VT marks a significant milestone — not just for Adagio, but for the millions of patients living with the burden of VT. We look forward to the results being shared by the investigators at HRS and the potential for these data to advance care for VT patients."","length":711,"tagName":"p"},{"type":"text","content":"The details of the late-breaking session are as follows:","length":56,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"colspan":"1","rowspan":"1","style":"background-color:#CCEEFF;width:20%;","val":[{"type":"text","content":"Presentation Title:","length":19,"tagName":"p","attribs":{}}]},{"colspan":"1","rowspan":"1","style":"background-color:#CCEEFF;width:80%;","val":[{"type":"text","content":"Effectiveness and Safety of Ultra-low Temperature Ablation of Ventricular Tachycardia in Patients with Structural Heart Disease: Outcomes of the Pivotal FULCRUM-VT Trial","length":169,"tagName":"p","attribs":{}}]}]},{"val":[{"colspan":"1","rowspan":"1","style":"width:20%;","val":[{"type":"text","content":"Time:","length":5,"tagName":"p","attribs":{}}]},{"colspan"...